You have full text access to this Open Access content

Cancer Science

Cover image for Vol. 106 Issue 3

Edited By: Yusuke Nakamura

Impact Factor: 3.534

ISI Journal Citation Reports © Ranking: 2013: 68/203 (Oncology)

Online ISSN: 1349-7006



Author Guidelines


Cancer Science has converted to OPEN ACCESS!

Cancer Science is fully open access from 1 January 2014.

Manuscripts accepted for publication will be published as open access articles, immediately free to read, download and share. Authors or their funder will be required to pay an Article Publication Charge upon acceptance. Please refer to the article publication charges page for more details including the JCA member discounts. For inquires, contact CancerScience@wiley.com.


Average submission to first decision is 16 days.

Cancer Science is the official journal of the Japanese Cancer Association. Cancer Science publishes original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Reports are intended to present highly significant and timely findings. They are not intended simply to be short versions of original articles. Case reports should describe new findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. Case reports of the following contents will not be accepted for publication: description of a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published. The following subject categories are covered:
• Basic and Clinical Immunology
• Carcinogenesis
• Cell, Molecular, and Stem Cell Biology
• Clinical Research
• Drug Discovery and Delivery
• Epidemiology and Prevention
• Genetics, Genomics, and Proteomics
• Inflammation and Virology
• Pathology

EDITORIAL REVIEW AND ACCEPTANCE

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two anonymous reviewers, the Associate Editor, and the Editor. Final acceptance or rejection rests with the Editors, who reserve the right to refuse any material for publication.
Authors may present names of potential reviewers and of reviewers whom they would prefer not to review the manuscript. The choice of reviewers remains the Editor's prerogative.
A manuscript requiring revision will be returned to the author by email, along with specific suggestions for revision. Authors should follow the instructions below to submit revised manuscripts:

• The author should reply to the suggestions clearly in the “Author’s Response” section by indicating places where revisions have been made, and/or by stating reasons for disregarding other suggestions if they are thought to be unacceptable.

• Modified parts should be highlighted using underline, colored font, the highlight function or track changes. The revised manuscript should then be resubmitted. Revised manuscripts should be returned to the Editorial Office within 2 months (minor revision) or 3 months (not acceptable in present form: major revision); otherwise they are considered to be new submissions and will be assigned a new date of receipt.

Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. They should be written in a clear, concise, direct style. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor and the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and to improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

Duplicate Publication and Scientific Fraud
In cases of suspected scientific misconduct (fabrication or falsification of data, double publication (including duplicate submission), or plagiarism), the journal will conduct a preliminary investigation. If scientific misconduct is found, the journal will contact the corresponding author’s institution and funding agencies. Cancer Science will not consider publication of any papers by the offending authors for a period of 1 year or longer depending on the circumstances of each case. Please also refer to the Editorial for the journal policy to plagiarism at: Plagiarism.

SUBMISSION OF MANUSCRIPTS

All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Manuscripts can be submitted online. For assistance, please contact the Editorial Office of Cancer Science at the address below:

Editorial Office of Cancer Science
c/o Wiley Japan Frontier Koishikawa Bldg., 4F
1-28-1 Koishikawa, Bunkyo-ku
Tokyo 112-0002 Japan
E-mail: CancerScience@wiley.com
Tel: 81 3 3830 1266
Fax: 81 3 5689 7278

All pages should be numbered consecutively in the top right-hand corner, beginning with the title page.

COVERING LETTER

A submission template of a covering letter is available at: http://mc.manuscriptcentral.com/societyimages/cas/Cover_Letter.pdf
A covering letter should be attached and the following information should be included:

A declaration that the paper is being submitted for consideration for publication in Cancer Science. The content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
All authors’ agreement: acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified.
Contact details at which the corresponding author can be contacted, including mailing address, telephone and fax numbers, and an email address.
If tables or figures have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.
The salient and novel findings of the paper in a concise paragraph.
The subject category that applies to the manuscript (please choose one only): Basic and Clinical Immunology; Carcinogenesis; Cell, Molecular, and Stem Cell Biology; Clinical Research; Drug Discovery and Delivery; Epidemiology and Prevention; Genetics, Genomics, and Proteomics; Inflammation and Virology; Pathology (effective from 1 November 2009).
• If the word count of the manuscript inevitably exceeds the limit, authors must state the reason for it. Exceeding the word count limit may be allowed at the editors’ discretion.
• For Case Reports, authors must state that consent for publication in print and electronically has been obtained from the patient or, if this is not possible, the next of kin.

AUTHOR MATERIAL ARCHIVE POLICY

Authors who require the return of any submitted material that is accepted for publication should inform the Editorial Office after acceptance. If no indication is given that author material should be returned, Wiley will dispose of all hardcopy and electronic material two months after publication.

DISCLOSURE

All authors should declare any financial support or relationship that may pose conflict of interest as “Disclosure Statement” between Acknowledgements and References sections. All authors will be required to complete a conflict of interest disclosure form as part of the initial manuscript submission process. The corresponding author is responsible for obtaining completed forms from all authors of the manuscript. Please visit here to check the details of the updated disclosure guideline. The latest form can be downloaded from here.

Please be advised that for articles which are accepted after April 1, 2012, in any case that the conflict of interest related to the articles submitted are not properly disclosed, there might be possibilities of imposing a penalty.

ETHICAL CONSIDERATIONS

Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Tokyo 2004).
All investigations on human subjects must include a statement that the subject gave informed consent. Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).
Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.


CLINICAL TRIALS

Cancer Science requires that all clinical trials submitted for its consideration are registered in a publicly accessible database. Authors should include the name of the trial register and their clinical trial registration number at the end of their summary. If you wish the editor(s) to consider an unregistered trial, please explain briefly why the trial has not been registered.


STYLE OF THE MANUSCRIPT

Manuscripts should follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors’ revised ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’.

Spelling. The Journal uses US spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary.

Units. All measurements must be given in SI or SI-derived units. Please go to the Bureau International des Poids et Mesures (BIPM) website for more information about SI units.

Abbreviations. Abbreviations used should be consistent with recommended international nomenclature. If there are few abbreviations used initially used the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only. If there are many non-standard abbreviations, a list of the abbreviations should be prepared. Click here for a list of Standard Abbreviations that can be used without definition.

Keywords. Five key words, for the purposes of indexing, should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/mesh/meshhome.html.

Nomenclature. Names of chemical compounds should conform to the International Union for Pure and Applied Chemistry (IUPAC) nomenclature and biochemical terms to those of the International Union of Biochemistry (IUB). Chemical substances should be referred to by the generic name only. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses. Names of enzymes should conform to the nomenclature recommended by IUB, the name to be followed by the enzyme number (EC) in parentheses.

Genetic nomenclature. Standard genetic nomenclature should be used. For further information, including relevant websites, authors should refer to the genetic nomenclature guide in Trends in Genetics (Elsevier Science, 1998).
Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345.’
Links are as follows:
DNA Data Bank of Japan (DDBJ)
EMBL Nucleotide Sequence Submissions
GenBank

PARTS OF THE MANUSCRIPT

Manuscripts parts should be presented in the following order: (i) title page, (ii) summary, abbreviations, and clinical trial register and their clinical registration number at the end of summary, (iii) text (including Introduction, Material and Methods, Results, Discussion), (iv) acknowledgments (if any), (v) disclosure statement (if any), (vi) references, (vii) appendices (if any), (viii) figure legends, (ix) a list of Supporting Information (if any; with codec used if they are videos), (x) tables (each table complete with title and footnotes) and (xi) figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

Word count:
Papers should not exceed the number of words set for each article type. For Original Article, the title page, summary, figure legends are included in the word count. For the other article types, the title page, summary, references, figure legends are included in the word count.

• Original article: up to 4000 words (excluding references), including a summary of no more than 250 words. The number of tables and figures is not limited. A submission template of an original article is available at: http://mc.manuscriptcentral.com/societyimages/cas/CAS_submission_template_original_Aug_2013.pdf
• Review article: 4000-5000 words (including up to 80 references), including a summary of no more than 250 words and 4–6 tables or figures in total. A submission template of a review article is available at: http://mc.manuscriptcentral.com/societyimages/cas/CAS_submission_template_review_article_Aug_2013.pdf
• Report: up to 2000 words (including up to 25 references), and up to 4 tables or figures in total, including a summary of no more than 250 words. Results and Discussion sections (which may be combined) and Acknowledgements. It must contain highly significant and timely findings.
• Case report: up to 2000 words (including up to 25 references), and up to 3 tables or figures in total. Summary should be up to 100 words. In the covering letter and in the text of the manuscript, authors must state that consent for publication in print has been obtained from the patient or, if this is not possible, the next of kin.
• Letter to the Editor: up to 1000 words (including 10 references), and up to 3 figures or tables in total.

File Format

Main document: Word.
• Tables: Word is preferred (tables of image data and grouping of text boxes should be avoided.) Excel will be accepted.
• Graphic figures: JPG/TIF/EPS (PDF is acceptable only for submission for ease of transmission during the review process.) Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .jpg or .tif files should be provided. Digital images supplied only as low-resolution files cannot be used.
• Line figures: EPS/ Word/Excel.
• Videos:QuickTime/ MPEG/AVI.

Please note that we cannot accept PowerPoint files. These files must be converted to one of the following file types: TIF/EPS/JPG (use maximum quality). Converting PowerPoint files frequently results in unexpected changes to the figures (e.g. missing or shifted text; shifted image elements). We recommend you not to create figures by PowerPoint. If you do try to convert from PowerPoint to one of these file types, be very careful to compare the final version to your original.

Title page
The title page should contain: (i) the title of the paper, (ii) the full names of the authors, (iii) the addresses of the institutions at which the work was carried out, (iv) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent. The present address of any author, if different from that where the work was carried out, should be supplied in a footnote, (v) the precise word count of the manuscript (excluding references for Original Articles; including references for Review Articles, Reports, Case Reports, and Letters to the Editor), (vi) number of tables/figures, (vii) quantity of supporting information.
The title should be short (preferably less than 120 letters), informative and contain the major key words. Do not use unnecessary words such as 'Study of' or 'Results on', or abbreviations in the title.

Summary
All articles must have a summary that states in 250 words or fewer the purpose, basic procedures, main findings and principal conclusions of the study. Data such as the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity should be included. The summary should not contain abbreviations or references.

Text
Authors should use the following subheadings to divide the sections of their manuscript: Introduction, Materials and Methods, Results and Discussion.
Introduction. The introduction should mention the purpose of the investigation, its relation to other work in the field, and the reasons for undertaking the research. Brief reference to the most relevant papers is sufficient.
Materials and Methods. Description of methods should be brief, but with sufficient detail to enable others to reproduce the experiments. When published procedures are used, the appropriate references should be cited. Only new and significant modifications of previously published procedures require complete description. Names of products and manufacturers with their locations (city and state/country) should be given and sources of animals and tumors should always be indicated.
Results. The results should be described concisely. Tables and figures should be used only if they are indispensable for the comprehension of data.
Discussion. The results should be interpreted and related to existing knowledge in the field. Information already given in the introduction or results should not be repeated.

Acknowledgments
The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Personal thanks and thanks to anonymous reviewers are not appropriate.

Disclosure
All authors should declare any financial support or relationship that may pose conflict of interest as “Disclosure Statement” between Acknowledgements and References sections. Examples of the disclosure statement will be found here.

References
The Vancouver system of referencing should be used (examples are given below). In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text.
In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first three followed by et al. Do not use ibid. or op cit. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list. When a reference is accepted but still in press, authors must submit it to reviewers if requested. If authors refuse to submit, the manuscript might be rejected because reviewers cannot review the context of the articles in press.

Names of journals should be abbreviated in the style used in Index Medicus. Authors are responsible for the accuracy of the references.

Journal article
1 Chenevix-Trench G, Spurdle AB, Gatei M et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002; 94: 205-15.

Journal articles published ahead of issue (print or online)
An online article that has not yet been published in an issue (therefore has no volume, issue or page numbers) can be cited by its Digital Object Identifier (DOI). The DOI will remain valid and allow an article to be tracked even after its allocation to an issue.
2 Okumura H, Ishii H, Pichiorri F et al . Fragile gene product, Fhit, in oxidative and replicative stress responses. Cancer Sci 2009 doi: 10.1111/j.1349-7006.2009.01168.x
Benz PJ, Soll J, Bölter B. Protein transport in organelles: The composition, function and regulation of the Tic complex in chloroplast protein import. FEBS Journal, 2009. doi: 10.1111/j.1742-4658.2009.06874.x

Book
3 Ringsven MK, Bond D. Gerontology and Leadership Skills for Nurses, 2nd edn. Albany, NY: Delmar Publishers, 1996.

Chapter in a Book
4 Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn. New York: Raven Press, 1995; 465–78.

Published on the World Wide Web
5 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis (Serial online) 1995 Jan–Mar; 1(1): (24 screens). [Cited 5 Jun 1996.] Available from URL: http://www.cdc.gov/ncidod/eid/index.htm

If the title of a paper is in English, French or German, it should be written in the original language. The present policy of Cancer Science is to reduce to a minimum citation of works which are not widely available to the international scientific community. However, if the title of an essential citation is in another language, such as Japanese or Russian, it should be translated into English, and the original language should be indicated in parentheses.

Appendices
These should be placed at the end of the paper, numbered in Roman numerals and referred to in the text. If written by a person other than the author of the main text, the writer’s name should be included below the title.

Tables
Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate sheet with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings. Tables should be submitted in Microsoft Word or Excel. Image files and groupings of text boxes should be avoided.

Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Figures should be sized to fit within the column (88 mm), intermediate (114 mm) or the full text width (180 mm). Materials of inappropriate size will be reduced by the Editorial Office. Magnifications should be indicated using a scale bar on the illustration. Figures should be supplied as separate files, with the figure number incorporated in the file name.

• Photographic and scanned images should be supplied meeting all three of the following criteria: (i) TIF or JPG file, (ii) 300 d.p.i. in resolution (or greater); (iii) 86 mm in image width (or greater).For submission, figures saved as .eps or .pdf files will be accepted, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .jpg, .eps or .tif files should be provided.
• Line figures should be supplied as EPS, Excel or Word files. Please provide the original version of these figures, that is, the file from the program they were drawn in.
• For figures that contain both line and photographic elements, please supply the line elements in the program in which they were drawn and the photographic elements in a separate file according to the instructions above.
• For more information regarding digital figures, please refer to our Electronic Artwork Information for Authors page.

Figure legends.
Type figure legends on a separate sheet. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Supporting Information
Supporting Information can be a useful way for an author to include important but ancillary information with the online version of an article. Examples of Supporting Information include additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related nonessential multimedia files. Supporting Information should be cited within the article text, and a descriptive legend should be included. It is published as supplied by the author, and a proof is not made available prior to publication; for these reasons, authors should provide any Supporting Information in the desired final format.
For further information on recommended file types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp
• Supporting figures, tables and text must be numbered Fig. S1, Fig. S2, etc., Table S1, Table S2, etc. and Doc. S1, Doc S2, etc, respectively.
• The availability of supporting information needs to be indicated in the main manuscript by a paragraph, to appear after the References, headed 'Supporting information' and providing titles of figures, tables and text.
• An author's website cannot be used as supporting information.

MANUSCRIPTS

Authors are required to provide electronic copies of their manuscripts to be submitted online. The following instructions should be adhered to:

• Lines should be double-spaced.
• Do not use the carriage return (Enter) at the end of lines within a paragraph.
• Turn the hyphenation option off; include only those hyphens that are essential to the meaning.
• Specify any special characters used to represent non-keyboard characters.
• Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German esszett) for ß (Greek beta).
• Use a tab, not spaces, to separate data points in tables. If you use a table editor function, ensure that each data point is contained within a unique cell (i.e. do not use carriage returns within cells).


- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

POST-ACCEPTANCE

ARTICLE PUBLICATION CHARGE

Manuscripts submitted after 30 August 2013 and accepted for publication will be published as open access articles, immediately free to read, download and share. You or your funder will be required to pay an Article Publication Charge on acceptance. Please refer to the article publication charges page for more details. Invited articles are free of any publication charges.

We will waive or discount charges for corresponding authors covered by the Research4Life Initiative (see the Wiley Open Access Waiver Country List). Authors of articles should be aware that publication of their manuscript cannot proceed without payment of the article publication charge. Authors are therefore requested to pay the article publication charge promptly i.e. within two weeks of receipt of the invoice.

OPEN ACCESS AGREEMENT (OAA)

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

The following license agreements are available:
Creative Commons Attribution Non-Commercial (CC-BY-NC) license
Creative Commons Attribution-Non-Commercial-NoDerivs (CC-BY-NC-ND) license.

From 1st April 2013, RCUK or Wellcome trust funded authors will be directed to sign the open access agreement under the terms of the Creative Commons Attribution (CC-BY) license in order to be funder compliant.

For more information on the terms and conditions of these licenses, please visit: http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html

PROOFS

It is essential that submitting authors supply an email address to which proofs can be emailed. Notification of the URL from where to download a Portable Document Format (PDF) typeset proof will be sent to the submitting author via email as a final check of the layout, tables and figures. (Note that the corresponding author will only receive the PDF typeset proof if he is the submitting author.) Alterations (other than the essential correction of errors) and addition/deletion of co-authors are unacceptable at PDF stage. Further instructions will be sent with the proof. The submitting author will be given a 48 hour turn-around time to return proof corrections. Submitting authors who will not be available to check their proofs should appoint someone to proofread their article. If the proof is not returned by the appointed date, it may be signed off on by the Editor or held over to the next issue.

ACCEPTED ARTICLES LITE

'Accepted Articles' have been accepted for publication and undergone full peer review but have not been through the copyediting, typesetting, pagination and proofreading process. Accepted Articles Lite are published online a few days after final acceptance, appear in abstract format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. A completed copyright form is required before a manuscript can be processed as an Accepted Article Lite.

COVER ART

Authors are invited to send in suggestions for colour images to be used as cover art for Cancer Science. The images should be visually exciting and should be relevant to any aspect of cancer research. Images should be uploaded in TIFF or EPS format at the highest possible resolution together with a brief description of the image provided.

EARLY VIEW

Cancer Science is covered by Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains vaild and can continue to be used to cite and access the article. More information about DOIs can be found at http://www.doi.org/faq.html

OFFPRINTS

A minimum of 50 offprints will be provided upon request, at the author's expense. These paper offprints may be ordered online. Please visit http://offprint.cosprinters.com/, fill in the necessary details and ensure that you type information in all of the required fields. If you have queries about offprints please email offprint@cosprinters.com

WILEY AUTHOR SERVICES

Authors of accepted papers will receive an invitation to sign up to Author Services that will enable them to track accepted articles through the production process. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the production editor to check on progress. Visit Author Services (http:/authorservices.wiley.com/bauthor/author.asp) for more details on online production tracking. This site also includes useful information such as copyright matters, ethics, electronic artwork guidelines, ways to optimize articles for search engines, FAQs and tips on article preparation, submission and more.

WILEY JOURNAL ONLINE

Visit the Cancer Science home page at http://wileyonlinelibrary.com/journal/cas for more information. For submission guidelines and digital graphics standards visit http://authorservices.wiley.com/bauthor/illustration.asp.

WILEY’S OPEN ACCESS JOURNAL, Cancer Medicine

This journal works together with Wiley’s Open Access Journal, Cancer Medicine, to enable rapid publication of good quality research that is unable to be accepted for publication by our journal. Authors will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of Cancer Medicine. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editor of Cancer Medicine will accept submissions that report well-conducted research which reaches the standard acceptable for publication. Accepted papers can be published rapidly, typically within 15 days of acceptance. Cancer Medicine is a Wiley Open Access journal and article publication fees apply. For more information please go to www.cancermedicinejournal.com/

SEARCH

SEARCH BY CITATION